Companies to Focus on Therapeutic Targets Showing Cause and Effect
Aitia has been featured in Huntington’s Disease News for its collaboration with UCB to develop a new treatment for Huntington’s disease. The article highlights Aitia’s expertise in Causal AI as “a new branch of artificial intelligence that goes beyond establishing links between variables: It makes decisions and predictions based on cause and effect.” The collaboration […]
UCB Enters Drug Discovery Collaboration with Aitia
Aitia latest strategic drug discovery collaboration with UCB, focused on the discovery and validation of novel drug targets and drug candidates for Huntington’s disease. The collaboration will combine the use of new drug targets for Huntington’s disease from Aitia’s Gemini Digital Twins with the expertise of UCB in preclinical model systems and drug research in neurodegeneration for advancing […]
Aitia Announces Oral Poster Presentation and Abstract at AACR
Aitia is looking forward to attend this year’s American Association for Cancer Research meeting #AACR23 taking place in Orlando, Florida, on April 14-19. Our team will be presenting a poster with our new results from our Multiple Myeloma Digital Twins model. Details of the poster session: Title: Infer cancer cell gene dependency in multiple myeloma using causal AI in-silico patient […]
Aitia Announces its Participation in the Upcoming AD/PD™ 2023 in Gothenburg, Sweden
Aitia is excited to announce its participation in the upcoming AD/PD™ 2023, a global conference on Alzheimer’s and Parkinson’s Diseases, to be held in Gothenburg, Sweden from March 28 – April 1.If you are interested in learning more about Aitia’s latest breakthroughs, particularly in the field of Alzheimer’s disease, we encourage you to schedule a […]
Join Aitia at BIO-Europe Spring 2023 in Basel, Switzerland
Aitia team will be attending the 17th annual BIO-Europe Spring conference in Basel, Switzerland, from March 20 to March 22, 2023. This event brings together over 2,800 executives from the biopharmaceutical industry, and we are excited to meet with fellow industry leaders to exchange ideas, forge new partnerships, and advance our shared goal of improving […]
Richard Harrison to Present at the Lab of the Future Congress
The Lab of the Future Congress USA is returning to Boston on March 9th and 10th 2023, and Team Aitia will be there to share our expertise on how Digital Twins are revolutionizing the drug discovery process and validating novel targets. Don’t miss the opportunity to attend our informative session on March 10th at 11:50 […]
Meet us at GAP Net Site Optimization Conference
If you are attending the upcoming GAP Net Site Optimization Conference in Austin, TX from Feb 24-26, join us for thought-provoking discussions on advancing Alzheimer’s disease clinical development. This conference will bring together the nation’s leading Alzheimer’s disease clinical trial research centers and GAP-Net partners to discuss the most recent advancements, challenges, and best practices […]
Research Identifies Potential New Biomarkers of Atherosclerotic Coronary Artery Disease
“This landmark result clearly demonstrates the power of causal AI and Digital Twins to reveal the hidden circuitry of cardiovascular disease from large-scale multi-omic data”, said Colin Hill, CEO and co-founder of Aitia. “Seventy years of cardiovascular biology including LDL, PCSK9, and Lp(a) were reconstructed in a hypothesis-free fashion in a few months, which created the […]
Becoming Aitia: Why GNS Shifted from AI Provider to Drug Discoverer
January 2023, GNS announced a rebrand as Aitia to focus on AI-enabled drug drug discovery. CEO Colin Hill told BioCentury the company considered the shift five years ago, seeing appetite from investors and pharma partners. “Aitia’s decision to move into drug discovery after more than 20 years as a technology partner is a bet on […]
New Biomarkers for Atherosclerosis Found Using Digital Twins
Newly identified markers of atherosclerotic coronary artery disease (ASCAD) were pinpointed in a study using digital twins. The work was carried out by multi-omics specialist G3 Therapeutics and AI company Aitia, which has Gemini Digital Twin technology. These new findings suggest triglyceride-rich LDL particles could be a novel diagnostic marker for ASCAD and could also […]